LIBTAYO may help shrink tumors.
LIBTAYO was studied in 2 clinical trials in patients with CSCC that had spread or could not be cured by surgery or radiation.
In 1 clinical trial, 46% (63 out of 137) of patients* saw an improvement in their advanced CSCC. In the same clinical trial, in a separate group of patients with CSCC that had spread who took LIBTAYO at the recommended dose,† 41% (23 out of 56) patients saw an improvement in their advanced CSCC.
In this trial, responses lasted between 1 month and more than 2 years (24.2+ months); plus sign (+) means the patient was still responding to treatment at their last assessment.
View full clinical trial results